Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer

Journal of Controlled Release

Volumn 201, Issue , 2015, Pages 90-99

  Poon, Christopher ^a   He, Chunbai ^a   Liu, Demin ^a   Lu, Kuangda ^a   Lin, Wenbin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Gemcitabine; Nanoscale coordination polymers; Oxaliplatin; Pancreatic ductal adenocarcinoma; Synergistic effect

Indexed keywords

CARDIOVASCULAR SYSTEM; DISEASES; DRUG PRODUCTS; DRUG THERAPY; ENZYME INHIBITION; NANOTECHNOLOGY;

COORDINATION POLYMERS; DUCTAL ADENOCARCINOMAS; GEMCITABINE; OXALIPLATIN; SYNERGISTIC EFFECT;

POLYMERS;

GEMCITABINE; NANOCARRIER; NANOSCALE COORDINATION POLYMER 1; NANOSCALE COORDINATION POLYMER 2; NANOSCALE COORDINATION POLYMER 3; OXALIPLATIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; NANOPARTICLE; PLATINUM COMPLEX; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RELEASE; DRUG UPTAKE; IC50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MONONUCLEAR PHAGOCYTE; MOUSE; NANOFABRICATION; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PARTICLE SIZE; PRIORITY JOURNAL; SURFACE CHARGE; SYNTHESIS; TUMOR VOLUME; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DRUG LIBERATION; HUMANS; MICE, NUDE; NANOPARTICLES; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; POLYMERS; TUMOR BURDEN;

EID: 84921752050     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.01.026     Document Type: Article

References (52)

1. S. Bunt, A. Mohr, J. Bailey, P. Grandgenett, and M. Hollingsworth Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer Cancer Immunol. Immunother. 62 2013 225 236
2. A.C. Society Cancer Facts & Figures 2013 2013 American Cancer Society Atlanta
3. F.G. El Kamar, M.L. Grossbard, and P.S. Kozuch Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care Oncologist 8 2003 18 34
4. R.J. Geer, and M.F. Brennan Prognostic indicators for survival after resection of pancreatic adenocarcinoma Am. J. Surg. 165 1993 68 72 (discussion 72-63)
5. R.S. King Gemcitabine. New first-line therapy for pancreatic cancer Cancer Pract. 4 1996 353 354
6. H.A. Burris III, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, M.R. Modiano, M.C. Cripps, R.K. Portenoy, A.M. Storniolo, P. Tarassoff, R. Nelson, F.A. Dorr, C.D. Stephens, and H.D.D. Von Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J. Clin. Oncol. 15 1997 2403 2413
7. L.W. Hertel, G.B. Boder, J.S. Kroin, S.M. Rinzel, G.A. Poore, G.C. Todd, and G.B. Grindey Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) Cancer Res. 50 1990 4417 4422
8. J.R. Mackey, R.S. Mani, M. Selner, D. Mowles, J.D. Young, J.A. Belt, C.R. Crawford, and C.E. Cass Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines Cancer Res. 58 1998 4349 4357
9. T. Oguri, H. Achiwa, S. Sato, Y. Bessho, Y. Takano, M. Miyazaki, H. Muramatsu, H. Maeda, T. Niimi, and R. Ueda The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity Mol. Cancer Ther. 5 2006 1800 1806
10. W. Plunkett, P. Huang, and V. Gandhi Preclinical characteristics of gemcitabine Anticancer Drugs 6 Suppl. 6 1995 7 13
11. J.R. Mackey, S.Y. Yao, K.M. Smith, E. Karpinski, S.A. Baldwin, C.E. Cass, and J.D. Young Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters J. Natl. Cancer Inst. 91 1999 1876 1881
12. B.-B.S. Zhou, and J. Bartek Targeting the checkpoint kinases: chemosensitization versus chemoprotection Nat. Rev. Cancer 4 2004 216 225
13. J. Lehar, A.S. Krueger, W. Avery, A.M. Heilbut, L.M. Johansen, E.R. Price, R.J. Rickles, G.F. Short III, J.E. Staunton, X. Jin, M.S. Lee, G.R. Zimmermann, and A.A. Borisy Synergistic drug combinations tend to improve therapeutically relevant selectivity Nat. Biotechnol. 27 2009 659 666
14. L.B. Saltz, S. Clarke, E. Diaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T.-S. Yang, F. Rivera, F. Couture, F. Sirzen, and J. Cassidy Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J. Clin. Oncol. 26 2008 2013 2019
15. R.S. Herbst, G. Giaccone, J.H. Schiller, R.B. Natale, V. Miller, C. Manegold, G. Scagliotti, R. Rosell, I. Oliff, J.A. Reeves, M.K. Wolf, A.D. Krebs, S.D. Averbuch, J.S. Ochs, J. Grous, A. Fandi, and D.H. Johnson Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J. Clin. Oncol. 22 2004 785 794
16. G. Giaccone, R.S. Herbst, C. Manegold, G. Scagliotti, R. Rosell, V. Miller, R.B. Natale, J.H. Schiller, J. von Pawel, A. Pluzanska, U. Gatzemeier, J. Grous, J.S. Ochs, S.D. Averbuch, M.K. Wolf, P. Rennie, A. Fandi, and D.H. Johnson Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1 J. Clin. Oncol. 22 2004 777 784
17. T. Conroy, F. Desseigne, M. Ychou, O. Bouche, R. Guimbaud, Y. Becouarn, A. Adenis, J.-L. Raoul, S. Gourgou-Bourgade, C. de la Fouchardiere, J. Bennouna, J.-B. Bachet, F. Khemissa-Akouz, D. Pere-Verge, C. Delbaldo, E. Assenat, B. Chauffert, P. Michel, C. Montoto-Grillot, and M. Ducreux FOLFIRINOX versus gemcitabine or metastatic pancreatic cancer N. Engl. J. Med. 364 2011 1817 1825
18. D.D. Von Hoff, T. Ervin, F.P. Arena, E.G. Chiorean, J. Infante, M. Moore, T. Seay, S.A. Tjulandin, W.W. Ma, M.N. Saleh, M. Harris, M. Reni, S. Dowden, D. Laheru, N. Bahary, R.K. Ramanathan, J. Tabernero, M. Hidalgo, D. Goldstein, E. Van Cutsem, X. Wei, J. Iglesias, and M.F. Renschler Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N. Engl. J. Med. 369 2013 1691 1703
19. V.T. DeVita Jr., R.C. Young, and G.P. Canellos Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer Cancer 35 1975 98 110
20. M.A. Shah, and G.K. Schwartz The relevance of drug sequence in combination chemotherapy Drug Resist. Updat. 3 2000 335 356
21. M. Ferrari Cancer nanotechnology: opportunities and challenges Nature Reviews Cancer. 5 2005 161 171
22. L.D. Mayer, T.O. Harasym, P.G. Tardi, N.L. Harasym, C.R. Shew, S.A. Johnstone, E.C. Ramsay, M.B. Bally, and A.S. Janoff Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice Mol. Cancer Ther. 5 2006 1854 1863
23. G.F.V. Ismael, D.D. Rosa, M.S. Mano, and A. Awada Novel cytotoxic drugs: old challenges, new solutions Cancer Treat. Rev. 34 2008 81 91
24. F. Danhier, O. Feron, and V. Preat To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery J. Control. Release 148 2010 135 146
25. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 2007 751 760
26. H. Devalapally, A. Chakilam, and M.M. Amiji Role of nanotechnology in pharmaceutical product development J. Pharm. Sci. 96 2007 2547 2565
27. B. Haley, and E. Frenkel Nanoparticles for drug delivery in cancer treatment Urol. Oncol. Semin. Orig. Invest. 26 2008 57 64
28. C. Louvet, R. Labianca, P. Hammel, G. Lledo, M.G. Zampino, T. Andre, A. Zaniboni, M. Ducreux, E. Aitini, J. Taieb, R. Faroux, C. Lepere, and A. de Gramont Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 23 2005 3509 3516
29. E. Poplin, Y. Feng, J. Berlin, M.L. Rothenberg, H. Hochster, E. Mitchell, S. Alberts, P. O'Dwyer, D. Haller, P. Catalano, D. Cella, and A.B. Benson III Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the eastern cooperative oncology group J. Clin. Oncol. 27 2009 3778 3785
30. A. Demols, M. Peeters, M. Polus, R. Marechal, F. Gay, E. Monsaert, A. Hendlisz, and J.L. Van Laethem Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study Br. J. Cancer 94 2006 481 485
31. C. Louvet, T. Andre, G. Lledo, P. Hammel, H. Bleiberg, C. Bouleuc, E. Gamelin, M. Flesch, E. Cvitkovic, and A. De Gramont Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study J. Clin. Oncol. 20 2002 1512 1518
32. E. Wong, and C.M. Giandomenico Current status of platinum-based antitumor drugs Chem. Rev. 99 1999 2451 2466
33. D. Liu, C. Poon, K. Lu, C. He, and W. Lin Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy Nat. Commun. 5 2014
34. W.J. Rieter, K.M. Pott, K.M.L. Taylor, and W. Lin Nanoscale coordination polymers for platinum-based anticancer drug delivery J. Am. Chem. Soc. 130 2008 11584 11585
35. K.M.L. Taylor-Pashow, J. Della Rocca, Z. Xie, S. Tran, and W. Lin Postsynthetic modifications of iron-carboxylate nanoscale metal-organic frameworks for imaging and drug delivery J. Am. Chem. Soc. 131 2009 14261 14263
36. M.S. Yavuz, Y. Cheng, J. Chen, C.M. Cobley, Q. Zhang, M. Rycenga, J. Xie, C. Kim, K.H. Song, A.G. Schwartz, L.V. Wang, and Y. Xia Gold nanocages covered by smart polymers for controlled release with near-infrared light Nat. Mater. 8 2009 935 939
37. J.E. Lee, N. Lee, H. Kim, J. Kim, S.H. Choi, J.H. Kim, T. Kim, I.C. Song, S.P. Park, W.K. Moon, and T. Hyeon Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery J. Am. Chem. Soc. 132 2010 552 557
38. R. Liu, Y. Zhang, X. Zhao, A. Agarwal, L.J. Mueller, and P. Feng pH-responsive nanogated ensemble based on gold-capped mesoporous silica through an acid-labile acetal linker J. Am. Chem. Soc. 132 2010 1500 1501
39. T.-C. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 70 2010 440 446
40. H. Xiao, W. Li, R. Qi, L. Yan, R. Wang, S. Liu, Y. Zheng, Z. Xie, Y. Huang, and X. Jing Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy J. Control. Release 163 2012 304 314
41. Y. Zhang, M. Huo, J. Zhou, and S. Xie PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel Comput. Methods Programs Biomed. 99 2010 306 314
42. T.E. Bapiro, F.M. Richards, M.A. Goldgraben, K.P. Olive, B. Madhu, K.K. Frese, N. Cook, M.A. Jacobetz, D.-M. Smith, D.A. Tuveson, J.R. Griffiths, and D.I. Jodrell A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with 19F NMR spectroscopy Cancer Chemother. Pharmacol. 68 2011 1243 1253
43. E. Raymond, S. Faivre, J.M. Woynarowski, and S.G. Chaney Oxaliplatin: mechanism of action and antineoplastic activity Semin. Oncol. 25 1998 4 12
44. J.M. Woynarowski, S. Faivre, M.C. Herzig, B. Arnett, W.G. Chapman, A.V. Trevino, E. Raymond, S.G. Chaney, A. Vaisman, M. Varchenko, and P.E. Juniewicz Oxaliplatin-induced damage of cellular DNA Mol. Pharmacol. 58 2000 920 927
45. E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, and E. Cvitkovic Cellular and molecular pharmacology of oxaliplatin Mol. Cancer Ther. 1 2002 227 235
46. O.M. Alian, A.S. Azmi, and R.M. Mohammad Network insights on oxaliplatin anti-cancer mechanisms Clin. Transl. Oncol. 1 2012 26
47. S.L. Cooke, and J.D. Brenton Evolution of platinum resistance in high-grade serous ovarian cancer Lancet Oncol. 12 2011 1169 1174
48. R.A. Fryer, B. Barlett, C. Galustian, and A.G. Dalgleish Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD® lenalidomide Anticancer Res. 31 2011 3747 3756
49. F. Levi, G. Metzger, C. Massari, and G. Miano Oxaliplatin: pharmacokinetics and chronopharmacological aspects Clin. Pharmacokinet. 38 2000 1 21
50. M. Rafi, H. Cabral, M.R. Kano, P. Mi, C. Iwata, M. Yashiro, K. Hirakawa, K. Miyazono, N. Nishiyama, and K. Kataoka Polymeric micelles incorporating (1,2-diaminocyclohexane)platinum (II) suppress the growth of orthotopic scirrhous gastric tumors and their lymph node metastasis J. Control. Release 159 2012 189 196
51. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392
52. H. Maeda, T. Sawa, and T. Konno Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS J. Control. Release 74 2001 47 61